Advertisement

Migraine and Other Primary Headaches

  • Bahman Jabbari

Abstract

Primary headaches consist of migraine, tension-type headaches, and trigeminal autonomic cephalalgias (e.g., cluster headache). Migraine and tension-type headaches are common and, in chronic form, are major causes of disability. Prospective double-blind and placebo-controlled studies have confirmed the efficacy of onabotulinumtoxinA (onaA) in chronic migraine (class A evidence). Follow-up of patients in PREEMPT studies with five cycles of onaA injections (over 56 weeks) attests to the tolerability and safety of this drug in chronic migraine and demonstrates progressive improvement of patient’s quality of life. In clinical practice, patients treated with onaA for more than 2 years describe their experience as very gratifying (attached videotapes). Studies using onaA in management of episodic migraine and chronic daily headaches have shown disappointing results and no evidence of efficacy. Investigations using botulinum neurotoxins (BoNTs) in management of tension-type headache have also provided negative results, but the results are confounded by selection of low-dose, suboptimal technique and selection of rigid primary outcome criteria. No blinded studies with BoNTs are available for trigeminal autonomic cephalalgias.

Keywords

Episodic migraine Chronic migraine Tension headache Chronic daily headache Autonomic neuralgias Cluster headache Botulinum toxin Botulinum neurotoxin OnabotulinumtoxinA OnaA 

Supplementary material

Video 4.1

(MOV 42983 kb)

Video 4.2

(MOV 26449 kb)

Video 4.3

(MOV 50010 kb)

Video 4.4

(MOV 34409 kb)

Video 4.5

(MOV 49389 kb)

Video 4.6

(MOV 28422 kb)

References

  1. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26:785–93.CrossRefPubMedGoogle Scholar
  2. Ashkenazi A, Sholtzow M, Shaw JW, Burstein R, Young WB. Identifying cutaneous allodynia in chronic migraine using a practical clinical method. Cephalalgia. 2007;27:111–7.CrossRefPubMedCentralPubMedGoogle Scholar
  3. Ashkenazi A, Blumenfeld A. OnabotulinumtoxinA for the treatment of headache. Headache. 2013;53(Suppl 2):54–61.CrossRefPubMedGoogle Scholar
  4. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache. 2007;47:486–99.CrossRefPubMedGoogle Scholar
  5. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803.CrossRefPubMedGoogle Scholar
  6. Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, Silberstein SD. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand. 2014;129:61–70.CrossRefPubMedCentralPubMedGoogle Scholar
  7. Becker WJ. Cluster headache: conventional pharmacological management. Headache. 2013;53:1191.CrossRefPubMedGoogle Scholar
  8. Bendtsen L, Evers S, Linde M, et al. EFNS guideline on the treatment of tension type headache: report of an EFNS task force. Eur J Neurol. 2010;17:1318–25.PubMedGoogle Scholar
  9. Beran RG, Spira PJ. Levetiracetam in chronic daily headache: a double-blind, randomized placebo-controlled study. (The Australian KEPPRA Headache Trial [AUS-KHT]). Cephalalgia. 2011;31:530–6.CrossRefPubMedGoogle Scholar
  10. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50:1406–18.CrossRefPubMedGoogle Scholar
  11. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000;1238:1703–9.CrossRefGoogle Scholar
  12. Cho ES, Hwang JY, Kim ST. A proposal to prevent the “Mephisto sign” side effect of botulinum toxin type A injection in chronic migraine. Yonsei Med J. 2013;54:1542–4.CrossRefPubMedCentralPubMedGoogle Scholar
  13. Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81:1191–6.CrossRefPubMedGoogle Scholar
  14. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125–33.CrossRefPubMedGoogle Scholar
  15. Diamond S, Dalessio DJ. Muscle contraction headache. In: Diamond D, Dalessio DJ, editors. The practicing physician’s approach to headache. 4th ed. Baltimore: Williams and Wilkins; 1986. p. 99–113.Google Scholar
  16. Diener HC, Holle D, Dodick D. Treatment of chronic migraine. Curr Pain Headache Rep. 2011;15:64–9.CrossRefPubMedGoogle Scholar
  17. Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, Ertas M, Lanteri-Minet M, Reuter U, Sánchez Del Río M, Schoenen J, Schwalen S, van Oene J, TOPMAT-MIG-303 Investigators Group. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2007;6:1054–62.CrossRefPubMedGoogle Scholar
  18. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–14.CrossRefPubMedGoogle Scholar
  19. Dodick DW, Mauskop A, Elkind AH, BOTOX CDH Study Group, et al. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo- controlled study. Headache. 2005;45:315–24.CrossRefPubMedGoogle Scholar
  20. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–36.CrossRefPubMedGoogle Scholar
  21. Elkind AH, O’Carroll P, Blumenfeld A, DeGryse R, Dimitrova R, BoNTA-024-026-036 Study Group. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain. 2006;7:688–96.CrossRefPubMedGoogle Scholar
  22. Evans RW. Diagnosis of headaches and medicolegal aspects. In: Evans, Mathew, editors. Handbook of headache. Philadelphia: Lippincott Wiliams and Wilkins; 2005, P1.Google Scholar
  23. Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine–a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004;24:838–43.CrossRefPubMedGoogle Scholar
  24. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolarynol. 1993;113:400–4.CrossRefGoogle Scholar
  25. Freitag FG, Diamond S, Diamond M, Urban G. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache. 2008;48:201–9.PubMedGoogle Scholar
  26. Freitag F. Managing and treating tension-type headache. Med Clin North Am. 2013;97:281–92.CrossRefPubMedGoogle Scholar
  27. Gelfand A, Goadsby PJ. A neurologist’s guide to acute migraine therapy in the emergency room. Neurohospitalist. 2012;2:51–9.CrossRefPubMedCentralPubMedGoogle Scholar
  28. Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia. 1997;17:153–8.CrossRefPubMedGoogle Scholar
  29. Goadsby P. Therapeutic prospects for migraine: can paradise be regained? Ann Neurol. 2013;74:423–34.Google Scholar
  30. Harden RN, Cottrill J, Gagnon CM, Smitherman TA, Weinland SR, Tann B, Joseph P, Lee TS, Houle TT. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study. Headache. 2009;49:732–43.CrossRefPubMedGoogle Scholar
  31. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd edition. Cephalalgia. 2004;24 Suppl 1:9–160.Google Scholar
  32. Hoffmann J, Goadsby PJ. Emerging targets in migraine. CNS Drugs. 2014;28:11–7.CrossRefPubMedGoogle Scholar
  33. Insinga RP, Ng-Mak DS, Hanson ME. Costs associated with outpatient, emergency room and inpatient care for migraine in the USA. Cephalagia. 2011;31:1570–5.CrossRefGoogle Scholar
  34. International Headache Society Classification Subcommittee. International classification of headache disorders, 2nd edition. Cephalalgia. 2004;24 suppl 1:1–160.Google Scholar
  35. Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, Burstein R. Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain. 2006;125:286–95.CrossRefPubMedCentralPubMedGoogle Scholar
  36. Lafrenière RG, Cader MZ, Poulin JF, Andres-Enguix I, Simoneau M, Gupta N, Boisvert K, Lafrenière F, McLaughlan S, Dubé MP, Marcinkiewicz MM, Amagopalan S, Ansorge O, Brais B, Sequeiros J, Pereira-Monteiro JM, Griffiths LR, Tucker SJ, Ebers G, Rouleau GA. A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nat Med. 2010;16:1157–60.CrossRefPubMedGoogle Scholar
  37. Lance J, Goadsby P. Mechanism and management of headache. 7th ed. Philadelphia: Elsevier; 2005.Google Scholar
  38. Lanteri-Minet M, Reuter U, Sánchez Del Río M, Schoenen J, Schwalen S, van Oene J, TOPMAT-MIG-303 Investigators Group. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2007;62:1054–62.Google Scholar
  39. Lipton RB, Varon SF, Grosberg B, McAllister PJ, Freitag F, Aurora SK, Dodick DW, Silberstein SD, Diener HC, DeGryse RE, Nolan ME, Turkel CC. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology. 2011;77:1465–72.CrossRefPubMedGoogle Scholar
  40. Lipton RB, Silberstein SD. The role of headache-related disability in migraine management: implications for headache treatment guidelines. Neurology. 2001;56(6 Suppl 1):S35–42.CrossRefPubMedGoogle Scholar
  41. Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101:366–70.CrossRefPubMedGoogle Scholar
  42. Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15:70–8.CrossRefPubMedGoogle Scholar
  43. Mathew NT, Reuventi U, Perez F. Transformed or evolutive migraine. Headache. 1987;27:102–6.CrossRefPubMedGoogle Scholar
  44. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, BOTOX CDH Study Group. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized double-blind, placebo-controlled trial. Headache. 2005;45:293–307.CrossRefPubMedGoogle Scholar
  45. Mathew NT. Pathophysiology of chronic migraine and mode of action of preventive medications. Headache. 2011;51(S2):84–92.CrossRefPubMedGoogle Scholar
  46. May A. Diagnosis and clinical features of trigemino-autonomic headaches. Headache. 2013;53:1470–8.PubMedGoogle Scholar
  47. Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007;120:2864–74.CrossRefPubMedGoogle Scholar
  48. Natoli J, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30:599–609.PubMedGoogle Scholar
  49. Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS, Jabbari B, Kaufmann HC, Schurch B, Silberstein SD, Simpson DM, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1707–14.CrossRefPubMedGoogle Scholar
  50. Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013;154 Suppl 1:S44–53.CrossRefPubMedGoogle Scholar
  51. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo- controlled, parallel design study. Cephalalgia. 2004;24:60–5.CrossRefPubMedGoogle Scholar
  52. Ozkurt B, Cinar O, Cevik E, Acar AY, Arslan D, Eyi EY, Jay L, Yamanel L, Madsen T. Efficacy of high-flow oxygen therapy in all types of headaches. A prospective, randomized, placebo-controlled trial. Am J Emerg Med. 2012;30:1760–4.CrossRefPubMedGoogle Scholar
  53. Padberg M, de Bruijn SF, de Haan RJ, Tavy DL. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia. 2004;24:675–80.CrossRefPubMedGoogle Scholar
  54. Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia. 2007;27:492–503.CrossRefPubMedGoogle Scholar
  55. Roberts WJ. A hypothesis on the physiological basis for causalgia and related pains. Pain. 1986;24:297–311.CrossRefPubMedGoogle Scholar
  56. Rollnik JD, Dengler R. Botulinum toxin (DYSPORT) in tension-type headaches. Acta Neurochir Suppl. 2002;79:123–6.PubMedGoogle Scholar
  57. Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, Nappi G. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain. 2011;12(4):427–33.CrossRefPubMedCentralPubMedGoogle Scholar
  58. Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM, BoNTA-009 Study Group. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med. 2007;8:478–85.CrossRefPubMedGoogle Scholar
  59. Schmitt WJ, Slowey E, Fravi N, Weber S, Burgunder JM. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache. 2001;41:658–64.CrossRefPubMedGoogle Scholar
  60. Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. JAMA. 1998;279:381–3.CrossRefPubMedGoogle Scholar
  61. Serrano D, Manack AN, Reed ML, Buse DC, Varon SF, Lipton RB. Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Value Health. 2013;16:31–8.CrossRefPubMedGoogle Scholar
  62. Silberstein SD. Preventive treatment of migraine: an overview. Cephalalgia. 1997;17:67–72.CrossRefPubMedGoogle Scholar
  63. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000;40:445–50.CrossRefPubMedGoogle Scholar
  64. Silberstein SD, Lipton RB. Chronic daily headache. Curr Opin Neurol. 2000;13:277–83.CrossRefPubMedGoogle Scholar
  65. Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC, BoNTA-039 Study Group. Botulinum toxin type a for the prophylactic treatment of chronic daily headache: a randomized, double blind, placebo controlled trial. Mayo Clin Proc. 2005;80:1126–37.CrossRefPubMedGoogle Scholar
  66. Silberstein SD, Göbel H, Jensen R, Elkind AH, Degryse R, Walcott JM, Turkel C. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia. 2006;26:790–800.CrossRefPubMedGoogle Scholar
  67. Silberstein SD. Treatment recommendations for migraine. Nat Clin Pract Neurol. 2008;4:482–9.CrossRefPubMedGoogle Scholar
  68. Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331:48–56.CrossRefPubMedGoogle Scholar
  69. Silberstein SD, Dodick DW. Migraine genetics: Part II. Headache. 2013;53:1218–29.CrossRefPubMedGoogle Scholar
  70. Silberstein SD, Vodovskaia N. Trigeminal autonomic cephalalgias other than cluster headache. Med Clin North Am. 2013;97:321–8.CrossRefPubMedGoogle Scholar
  71. Silberstein SD. The use of botulinum neurotoxin in management of headache disorder. In: Troung, Hallet, Zachary, Dressler, editors. Manual of botulinum toxin therapy. Cambridge: Cambridge Press; 2013. p. 222–32.Google Scholar
  72. Schulte-Mattler WJ, Krack P, BoNTTH Study Group. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain. 2004;109(1–2):110–4.CrossRefPubMedGoogle Scholar
  73. Sostak P, Krause P, Förderreuther S, Reinisch V, Straube A. Botulinum toxin type-A therapy in cluster headache: an open study. J Headache Pain. 2007;8:236–41.CrossRefPubMedCentralPubMedGoogle Scholar
  74. Straube A, Empl M, Ceballos-Baumann A, Tölle T, Stefenelli U, Pfaffenrath V, Dysport Tension-Type Headache Study Group. Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache - a multicentre, double-blind, randomized, placebo-controlled study. Eur J Neurol. 2008;15:205–13.CrossRefPubMedGoogle Scholar
  75. Vo AH, Satori R, Jabbari B, Green J, Killgore WD, Labutta R, Campbell WW. Botulinum toxin type-A in the prevention of migraine: a double-blind controlled trial. Aviat Space Environ Med. 2007;78(5 Suppl):B113–8.PubMedGoogle Scholar
  76. Waeber C, Moskowitz M. Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology. 2003;61 suppl 4:S9–20.CrossRefPubMedGoogle Scholar
  77. Wiegand H, Erdmann G, Welhoner HH. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol. 1976;292:161–5.CrossRefPubMedGoogle Scholar
  78. Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain. 2008;9:37–41.CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Bahman Jabbari
    • 1
  1. 1.Botulinum Toxin Treatment ProgramYale School of MedicineNew HavenUSA

Personalised recommendations